| MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease M Eslam, AJ Sanyal, J George, A Sanyal, B Neuschwander-Tetri, ... Gastroenterology 158 (7), 1999-2014. e1, 2020 | 2925 | 2020 |
| Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial BA Neuschwander-Tetri, R Loomba, AJ Sanyal, JE Lavine, ML Van Natta, ... The Lancet 385 (9972), 956-965, 2015 | 2519 | 2015 |
| A multisociety Delphi consensus statement on new fatty liver disease nomenclature ME Rinella, JV Lazarus, V Ratziu, SM Francque, AJ Sanyal, F Kanwal, ... Hepatology 78 (6), 1966-1986, 2023 | 2511 | 2023 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1170 | 2019 |
| Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening V Ratziu, SA Harrison, S Francque, P Bedossa, P Lehert, L Serfaty, ... Gastroenterology 150 (5), 1147-1159. e5, 2016 | 1167 | 2016 |
| Fructose consumption as a risk factor for non-alcoholic fatty liver disease X Ouyang, P Cirillo, Y Sautin, S McCall, JL Bruchette, AM Diehl, ... Journal of hepatology 48 (6), 993-999, 2008 | 1095 | 2008 |
| AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease ME Rinella, BA Neuschwander-Tetri, MS Siddiqui, MF Abdelmalek, ... Hepatology 77 (5), 1797-1835, 2023 | 1012 | 2023 |
| Fructose and sugar: A major mediator of non-alcoholic fatty liver disease T Jensen, MF Abdelmalek, S Sullivan, KJ Nadeau, M Green, C Roncal, ... Journal of hepatology 68 (5), 1063-1075, 2018 | 987 | 2018 |
| Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease MF Abdelmalek, A Suzuki, C Guy, A Unalp‐Arida, R Colvin, RJ Johnson, ... Hepatology 51 (6), 1961-1971, 2010 | 896 | 2010 |
| Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps A Lonardo, F Nascimbeni, S Ballestri, DL Fairweather, S Win, TA Than, ... Hepatology 70 (4), 1457-1469, 2019 | 798 | 2019 |
| A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis SL Friedman, V Ratziu, SA Harrison, MF Abdelmalek, GP Aithal, ... Hepatology 67 (5), 1754-1767, 2018 | 735 | 2018 |
| Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study MF Abdelmalek, P Angulo, RA Jorgensen, PB Sylvestre, KD Lindor Official journal of the American College of Gastroenterology| ACG 96 (9 …, 2001 | 690 | 2001 |
| Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests RFA Logan, J Patnick, C Nickerson, L Coleman, MD Rutter, ... Gut 61 (10), 1439-1446, 2012 | 620 | 2012 |
| Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled … A Sanyal, ED Charles, BA Neuschwander-Tetri, R Loomba, SA Harrison, ... The Lancet 392 (10165), 2705-2717, 2018 | 536 | 2018 |
| Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease MS Siddiqui, R Vuppalanchi, ML Van Natta, E Hallinan, KV Kowdley, ... Clinical Gastroenterology and Hepatology 17 (1), 156-163. e2, 2019 | 485 | 2019 |
| A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis SA Harrison, P Bedossa, CD Guy, JM Schattenberg, R Loomba, R Taub, ... New England Journal of Medicine 390 (6), 497-509, 2024 | 474 | 2024 |
| A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH SM Francque, P Bedossa, V Ratziu, QM Anstee, E Bugianesi, AJ Sanyal, ... New England Journal of Medicine 385 (17), 1547-1558, 2021 | 467 | 2021 |
| Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease ML Palmeri, MH Wang, NC Rouze, MF Abdelmalek, CD Guy, B Moser, ... Journal of hepatology 55 (3), 666-672, 2011 | 463 | 2011 |
| Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis ZM Younossi, R Loomba, QM Anstee, ME Rinella, E Bugianesi, ... Hepatology 68 (1), 349-360, 2018 | 462 | 2018 |
| NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial SA Harrison, ME Rinella, MF Abdelmalek, JF Trotter, AH Paredes, ... The Lancet 391 (10126), 1174-1185, 2018 | 446 | 2018 |
Arun SanyalVerified email at mcvh-vcu.edu
